CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

Forbion Announces its New General Partner

Forbion Announces its New General...

3D-Bioprinted Platform For Comprehensive Cell Analysis

3D-Bioprinted Platform For...

Significance of Bioanalytical Services

Significance of Bioanalytical Services

Enhancing Bioanalytical Workflows with Latest Technology

Enhancing Bioanalytical Workflows...

How Remote Monitoring can Improve Healthcare Delivery?

How Remote Monitoring can Improve...

What You Should Know About Bioanalytical Method Validation

What You Should Know About...

What are Some Popular Applications of Analytical Testing Techniques?

What are Some Popular Applications of...

The Role of Technology in Transforming Bioanalysis

The Role of Technology in...

Forbion Announces its New General Partner

Forbion Announces its New General...

MediciNova Secures Patent for MN-166 and Riluzole

Life Sciences Review Life Sciences Review | Tuesday, May 18, 2021
Tweet

MediciNova announces that it had received a Notice of Intention to Grant from the European Patent Office for MN-166 (ibudilast) and riluzole for the medication of amyotrophic lateral sclerosis (ALS).


FREMONT, CA: MediciNova, Inc., a biopharmaceutical firm listed on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, has announced that it has got a Notice of Intention to Grant from the European Patent Office for a pending patent application covering the combination of MN-166 (ibudilast) and riluzole for the medication of amyotrophic lateral sclerosis (ALS). 


Once issued, the patent resulting from this authorized patent application is estimated to expire no earlier than November 2035. The permitted claims cover the use of MN-166 (ibudilast) and riluzole to treat a patient with ALS, where the treatment results in stabilizing the patient's scleroses condition. The allowed claims for MN-166 (ibudilast) and riluzole cover a massive range of doses and dosing regimens.


Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to receive notice that this new patent will be granted. Previously, similar patents were granted in the U.S. and Japan based on data from our first clinical trial in ALS patents. 


We previously announced results of a responder analysis which found that the proportion of responders, defined as stable or improved in ALS functional score, muscle test and subjective ALSAQ-5 quality of life assessment, was higher in the MN-166 plus riluzole-treated group compared to the riluzole-only group. We believe this new patent could substantially increase the potential value of MN-166. We are currently conducting a Phase 3 clinical trial with ALS patients in the U.S. and Canada using MN-166 plus riluzole. The U.S. FDA granted both orphan-drug designation and fast-track designation to MN-166 for the treatment of ALS, and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS."


MediciNova, Inc. is a publicly-traded biopharmaceutical organization established on developing advanced, small-molecule therapeutics for the treatment of diseases with unmet medical requirements, with a primary commercial emphasis on the United States market.


Weekly Brief

loading
Top 10 Bioanalytical Service Companies in Europe - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/medicinova-secures-patent-for-mn166-and-riluzole--nwid-362.html